AACR 2026 發布癌症研究新進展
New Cancer Research Advancements Presented at AACR 2026
2026年美國癌症研究協會（AACR）年度會議於今年四月在聖地牙哥舉行，展示了癌症研究的重大突破。
The AACR Annual Meeting 2026, held this April in San Diego, showcased major leaps in cancer research.
其中一大亮點是利用循環腫瘤DNA（ctDNA）來檢測實體腫瘤中的微量殘留病灶（MRD），這能比臨床復發提早十個月發現病情。
A highlight was the use of circulating tumor DNA (ctDNA) to detect Minimal Residual Disease (MRD) in solid tumors, offering a 10-month head start on clinical relapse.
癌症預防也備受關注，專家致力於透過基因組與環境篩檢來阻斷「零期」癌症。
Prevention also took center stage, with experts focusing on intercepting "Stage 0" cancers through genomic and environmental screening.
人工智慧的影響巨大，首次舉辦了專門討論數位孿生與自動化診斷的全體大會。
Artificial Intelligence made a massive impact, with its first dedicated plenary session covering digital twins and automated diagnostics.
研究人員也探討了早發型癌症令人擔憂的上升趨勢，特別是大腸直腸癌案例，並發現其獨特的免疫特徵。
Researchers also investigated the alarming rise in early-onset cancers, particularly in colorectal cases, noting unique immune features.
治療方面的進展同樣令人印象深刻，新型CAR-T療法正邁向實體腫瘤治療，mRNA疫苗也開始與檢查點抑制劑結合使用。
Therapeutic progress was equally impressive, as new CAR-T therapies move into solid tumors and mRNA vaccines are paired with checkpoint inhibitors.
